- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05494697
Ampligen Compared to No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma
A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Diane Young
- Phone Number: 352-448-7797
- Email: diane.young@aimimmuno.com
Study Contact Backup
- Name: Kher Lee Ng, PhD
- Phone Number: 301-528-7000
- Email: kherleen@amarexcro.com
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- Recruiting
- Nebraska Medical Center
-
Contact:
- Jessica E Delaney, BSN
- Phone Number: 402-559-8711
- Email: jessdelaney@unmc.edu
-
Principal Investigator:
- Kelsey Klute, MD
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Recruiting
- Gabrail Cancer Center Research
-
Contact:
- Carrie Smith
- Phone Number: 208 330-492-3345
- Email: csmith@gabrailcancercenter.com
-
Principal Investigator:
- Nashat Y. Gabail, MD
-
-
Washington
-
Seattle, Washington, United States, 98101
- Recruiting
- Virginia Mason Medical Center
-
Principal Investigator:
- Vincent Picozzi, MD
-
Contact:
- Colette Treperinas
- Phone Number: 206-287-6286
- Email: colette.treperinas@vmfh.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histological diagnosis of pancreatic adenocarcinoma confirmed pathologically: Unresectable pancreatic cancer; locally advanced pancreatic cancer.
- Measurable disease per RECIST v.1.1.
- Completion of at least four (4) months of first line FOLFIRINOX treatment and no disease progression per RECIST v.1.1 as confirmed by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan 4 to 6 weeks after last FOLFIRINOX treatment.
- Male or non-pregnant, non-lactating female, ≥18 years or age.
Negative pregnancy test for female subjects. Women of child-bearing potential (WOCBP) and Women not of child-bearing potential are eligible to participate. Both women of child-bearing potential and women of non-child-bearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study and for 90 days after last treatment.
Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile or two years post-menopausal. All male subjects/partners must agree to use a condom consistently and correctly for the duration of the study and for 90 days after last treatment. In addition, subjects may not donate sperm for the duration of the study and for 90 days after the last treatment.
Females who are less than two (2) years post-menopausal, those with tubal ligations and those using contraception must have a negative serum pregnancy test at baseline within the one (1) week prior to the first study medication infusion. Every six weeks, and at study termination a pregnancy test should be performed, either serum or urine stick test. However, if the urine result is positive, a serum pregnancy test will be performed.
Any pregnancy that occurs while taking Ampligen® should be recorded using a Pregnancy Report Form and reported immediately to AIM ImmunoTech, Inc.
- Provide signed written informed consent and willingness, ability to comply with study requirements.
- Minimum weight of 40kg at baseline.
- Karnofsky Performance Status of 80 or higher at baseline.
- Subject must have a projected life expectancy of ≥ 3 months in the opinion of the Investigator.
- Subject has adequate organ function by the following laboratory assessments at baseline (obtained ≤ 28 days prior to Visit 2/First Treatment:
Hematologic:
Platelets ≥ 100×109/L Hemoglobin ≥ 9.0 g/dL Absolute Neutrophil Count (ANC) ≥ 1.5×109/L Absolute lymphocyte count ≥ 3 x 109/L
Hepatic:
AST/ALT ≤ 3×ULN (if liver metastases are present, ≤ 5×ULN) Alkaline phosphatase ≤ 2.0×ULN (if liver metastases are present, ≤ 5×ULN) Total bilirubin ≤ 1.5×ULN Albumin ≥ 3.0 g/dL
Renal:
Creatinine clearance ≥ 60 mL/min using the Cockcroft-Gault formula.
Coagulation:
PT-INR and APTT within normal limits
Exclusion Criteria:
- Diagnosis of islet neoplasm acinar cell carcinoma, non-adenocarcinoma (i.e., lymphoma, sarcoma), adenocarcinoma originating from the biliary tree, or cystadenocarcinoma.
- Subjects who have surgically resectable locally advanced pancreatic adenocarcinoma following treatment with FOLFIRINOX.
- Subject has received prior treatment with Ampligen®.
- Therapy with investigational drugs within 6 weeks of beginning study medication.
- History of prior malignancy, except for adequately treated in situ cancer, basal cell, squamous cell skin cancer, or other cancers (e.g., breast, prostate) for which the subject has been disease-free for at least 3 years. Subjects with prior cancer that is adequately controlled per the judgement of the Investigator will not be excluded from the study.
- Any serious medical condition, laboratory abnormality, psychiatric illness, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for the study.
- Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous (IV) treatment for infection(s).
- Known history of positivity (regardless of immune status) for human immunodeficiency virus (HIV).
- Known history of, chronic active, or active viral hepatitis A, B, or C infection
- Clinically significant bleeding within 2 weeks prior to Randomization (e.g., gastrointestinal [GI] bleeding, intracranial hemorrhage).
- Pregnant or lactating women.
- Myocardial infarction within the last 6 months prior to Randomization, symptomatic congestive heart failure (New York Heart Association Classification > Class II), unstable angina, or unstable cardiac arrhythmia requiring medication.
- Subjects with abnormal electrocardiogram (ECG) at baseline QTc interval >470 ms (calculated using both the Bazett's and Fridericia's corrections).
- Subjects with positive germline BRCA (gBRCA) mutations.
- Clinically significant ascites defined as requiring ≥ 1 paracentesis every 2 weeks.
- Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy), within 28 days prior to Randomization or anticipated surgery during the study period.
- Prior history of receiving immune checkpoint inhibitors (anti-CTLA4, anti-PD1, anti-PD- L1).
- Inability to return for scheduled treatment and assessments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ampligen / rintatolimod
Subjects will receive rintatolimod [intravenous (IV)], up to 400 mg twice weekly until disease progression.
|
Rintatolimod (poly I : poly C12U)
Other Names:
|
No Intervention: Control Group / No Treatment
Subjects will be followed / no treatment until evidence of disease progression.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS)
Time Frame: Visit 2/First Treatment until disease progression, death, or end of study up to 42 months
|
PFS is defined as the time, in months, from date of randomization to date of the first documentation of definitive disease progression as per RECIST v1.1 (the initial progressive disease (PD)) or death due to any cause.
|
Visit 2/First Treatment until disease progression, death, or end of study up to 42 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Visit 2/First Treatment to death due to any cause, or end of study up to 182 weeks.
|
OS is defined as patients who are alive at time of analysis
|
Visit 2/First Treatment to death due to any cause, or end of study up to 182 weeks.
|
Overall Survival (OS) at 1 year
Time Frame: Visit 2/First Treatment to death due to any cause.at 1 year
|
OS is defined as the time from date of Visit 2/First Treatment to death due to any cause.
|
Visit 2/First Treatment to death due to any cause.at 1 year
|
Objective Response Rate (ORR)
Time Frame: Visit 2/First Treatment until disease progression, death, or end of study up to 42 months
|
ORR is defined as the proportion of subjects who achieve a Complete Response (CR) or Partial Response (PR) as assessed by RECIST v1.1
|
Visit 2/First Treatment until disease progression, death, or end of study up to 42 months
|
Duration of Response (DoR)
Time Frame: Visit 2/First Treatment until disease progression, death, or end of study up to 42 months
|
DoR is defined as the time from the date of the first documentation of objective tumor response (CR or PR) to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurs first.
|
Visit 2/First Treatment until disease progression, death, or end of study up to 42 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: David R Strayer, MD, AIM ImmunoTech Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMP-270
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
Clinical Trials on Rintatolimod
-
AIM ImmunoTech Inc.Available
-
AIM ImmunoTech Inc.Amarex Clinical ResearchCompletedLong COVID | Post COVID-19 ConditionUnited States
-
Joachim Aerts, MD PhDAIM ImmunoTech Inc.; AstraZeneca BVRecruiting
-
Robert EdwardsMerck Sharp & Dohme LLC; AIM ImmunoTech Inc.RecruitingOvarian Cancer RecurrentUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCWithdrawnMetastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Microsatellite Stable | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA... and other conditionsUnited States
-
AIM ImmunoTech Inc.TerminatedHIV Infection | HIV SeropositivityUnited States
-
AIM ImmunoTech Inc.CompletedHIV Infection | HIV SeropositivityUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Roswell Park Cancer InstituteAIM ImmunoTech Inc.CompletedEstrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple -Negative Breast Cancer | Anatomic Stage IV Breast Cancer AJCCUnited States
-
AIM ImmunoTech Inc.Terminated